SCHEMBL5024895

SCHEMBL5024895

Nc1ncnc2c1ncn2[C@@H]1O[C@H](COO)[C@@H](O)[C@H]1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 3/20 0.76
SMN1; SMN2 Q16637 3/20 0.76
ADORA3 P0DMS8 2/20 0.76
ADORA2A P29274 2/20 0.76
ADORA2B P29275 2/20 0.76
DPP4 P27487 1/20 0.76
MEN1 O00255 1/20 0.76
SLC28A1 O00337 1/20 0.76
MAP3K7 O43318 1/20 0.76
SLC28A2 O43868 1/20 0.76
GAPDH P04406 1/20 0.76
MAPK1 P28482 1/20 0.76
STAT6 P42226 1/20 0.76
PI4KA P42356 1/20 0.76
KMT2A Q03164 1/20 0.76
PI4K2B Q8TCG2 1/20 0.76
DOT1L Q8TEK3 1/20 0.76
SLC29A1 Q99808 1/20 0.76
PI4K2A Q9BTU6 1/20 0.76
SLC28A3 Q9HAS3 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12963362 1.00 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL7803298 1.00 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL10997946 0.91 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL2040670 0.91 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL481524 0.91 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL17440176 0.91 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
Water SCHEMBL4262656 0.90 ADORA1 (0.71) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL384075 0.89 ADORA1 (0.74) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL8328542 0.89 ADORA1 (0.74) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL15788449 0.89 ADORA1 (0.74) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104686208-A Usage and method for detection, processing and artificial cultivation of tussah cordyceps militaris taken as traditional Chinese medicinal materials BEIJING MAILLARD TRADITIONAL CHINESE MEDICINE DECOCTION PIECES TECHNOLOGY CO LTD 2015-06-10 CN claimed
US-11976296-B2 Means and methods for generating midbrain organoids UNIVERSITÉ DU LUXEMBOURG (LU) 2024-05-07 US disclosed
CN-104686208-B A kind of artificial culturing method of toothed oak Cordyceps militaris Chinese medicine, processing, detection and application thereof 北京美拉德中药饮片科技有限公司 2019-08-23 CN disclosed
CN-104686208-A Usage and method for detection, processing and artificial cultivation of tussah cordyceps militaris taken as traditional Chinese medicinal materials BEIJING MAILLARD TRADITIONAL CHINESE MEDICINE DECOCTION PIECES TECHNOLOGY CO LTD 2015-06-10 CN disclosed
EP-1903873-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS THE UNIVERSITY OF ROCHESTER (US) 2008-04-02 EP disclosed
WO-2006135602-A2 HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS UNIVERSITY OF ROCHESTER (US) 2006-12-21 WO disclosed
US-7049303-B2 Inhibition of viruses MEDICAL RESEARCH COUNCIL (GB) 2006-05-23 US disclosed
US-20050043268-A1 Inhibition of viruses MEDICAL RESEARCH COUNCIL (GB) 2005-02-24 US disclosed
WO-1998001459-A1 NOVEL N-ALKOXYADENINE DERIVATIVES ACTING AS CYTOKINE INHIBITORS NOVO NORDISK A/S (DK) 1998-01-15 WO disclosed
WO-1997033590-A1 A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS NOVO NORDISK A/S (DK) 1997-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043268-A1 Inhibition of viruses RNASE1, HNRNPA1, RNASEH1 ADORA1 237/4885SMN1; SMN2 421/4885ADORA3 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.